A practical clinical pharmacology approach to antiplatelet therapy in patients with dengue

Dengue is usually associated with one familiar medication warning: avoid aspirin and NSAIDs because of bleeding risk.

But what happens when aspirin is not being taken for fever or pain?

What if the patient is taking aspirin plus a P2Y12 inhibitor because they recently underwent coronary angioplasty and stent placement?

That is a much more difficult clinical problem.

In such patients, clinicians are balancing two competing hazards:

• Bleeding, driven by dengue-associated thrombocytopenia, platelet dysfunction, endothelial injury, capillary leakage and coagulopathy.

• Coronary thrombosis, particularly when antiplatelet therapy is interrupted after recent PCI or ACS.

The key question is therefore not simply: “What is the platelet count?”

It is: “How important is continued antiplatelet therapy for this particular patient, and how does that risk compare with the patient's current bleeding risk from dengue?”

Dengue-specific evidence remains limited, and newer recommendations are largely based on expert consensus rather than randomized trials in dengue patients.

Why does DAPT become difficult in dengue?

Dual antiplatelet therapy (DAPT) usually consists of aspirin plus a P2Y12 inhibitor, such as clopidogrel, ticagrelor or prasugrel.

The two drugs inhibit different pathways of platelet activation:

• Aspirin inhibits thromboxane A₂-mediated platelet activation.

• P2Y12 inhibitors inhibit ADP-mediated platelet activation and amplification.

This combination is central to preventing coronary thrombotic events following ACS and PCI.

Dengue changes the background against which these drugs are being used.

Thrombocytopenia is common, platelet function can be abnormal, and endothelial and coagulation abnormalities can increase bleeding risk. The critical phase, commonly around days 3–7 of illness, is particularly important because plasma leakage and hemodynamic complications can develop during this period.

At the same time, premature interruption of antiplatelet therapy after coronary stenting can expose the patient to thrombotic complications.

Start with one question: Why is the patient on DAPT?

Before changing therapy, establish:

1. Why was DAPT started?

2. When was the PCI or ACS?

3. Is the patient still within the intended DAPT period?

4. Is there a particularly high thrombotic-risk feature?

These questions can change the clinical context substantially.

Recent PCI

A patient who received a coronary stent very recently is in a different situation from someone whose PCI occurred years ago.

Interruption of DAPT early after stenting can be particularly concerning because of the potential for stent thrombosis. Recent 2026 dengue-specific recommendations therefore give particular attention to patients with very recent PCI. (Frontiers)

Prior PCI with completion of the recommended DAPT period

A patient whose PCI occurred in the past and who has already completed the guideline-recommended DAPT period is in a different antithrombotic context.

For example, the 2023 AHA/ACC chronic coronary disease guideline recommends, for patients with chronic coronary disease undergoing PCI, DAPT with aspirin and clopidogrel for 6 months followed by single antiplatelet therapy, while allowing shorter strategies in selected patients. (JACC)

This does not mean that every patient beyond six months can automatically have antiplatelet therapy stopped. The original indication, prior ACS, ischemic risk and reason for prolonged therapy still matter.

Don't look at the platelet count in isolation

A platelet count is important. But a single platelet value does not tell the whole story.

Consider two patients:

Patient A

• Platelets: 50,000/mm³

• Stable count

• No bleeding

• Hematocrit stable

• Dengue entering recovery

Patient B

• Platelets: 50,000/mm³

• Rapidly falling from 120,000/mm³

• Rising hematocrit

• Evidence of plasma leakage

• Mucosal bleeding

The numerical platelet count is identical. The clinical situation is not. The platelet trajectory, bleeding status, hematocrit, plasma leakage, hemodynamics and dengue phase all matter.

What does the Indian dengue guideline say?

The National Guidelines for Clinical Management of Dengue Fever 2023 have a specific section addressing dengue in patients with coronary artery disease and heart failure.

The guideline recognizes that CAD patients may already be receiving antiplatelet therapy and that this can increase bleeding concerns during dengue.

It recommends careful monitoring of patients receiving antiplatelet or anticoagulant therapy.

Importantly, it states that aspirin and other antiplatelet agents may be discontinued at the initial stage when the platelet count is below 100,000/mm³ or when minor or major bleeding occurs with evidence of capillary leakage. (NCVBDC)

However, this statement needs to be interpreted carefully.

The <100,000/mm³ value should not be treated as a universal cardiology rule saying “stop both antiplatelets in every patient.”

It is part of a dengue-management guideline, and the same guideline emphasizes the difficulty of managing CAD patients during dengue.

Therefore, the patient's coronary indication and time since PCI must be considered alongside the bleeding risk.

What do newer recommendations add?

Two 2026 expert position papers provide more detailed frameworks.

A Frontiers in Tropical Diseases position paper recommends individualized assessment and frequent reassessment. It recommends avoiding intravenous P2Y12 antiplatelet agents in thrombocytopenia and generally favors clopidogrel-based DAPT in selected ACS/post-PCI patients when DAPT remains necessary. It also discusses shortening DAPT and transitioning to single antiplatelet therapy when clinically feasible. (Frontiers)

A Brazilian 2026 position statement provides additional platelet-count-based recommendations. For example, it identifies patients with angioplasty within 30 days as a particularly high-thrombotic-risk group and provides different approaches according to platelet count and time since angioplasty. (ABCCardiol)

But these recommendations are position statements, not dengue-specific randomized clinical trials.

What about clopidogrel versus ticagrelor or prasugrel?

When a P2Y12 inhibitor is still required during significant thrombocytopenia, recent dengue-specific expert recommendations generally favor clopidogrel over the more potent P2Y12 inhibitors.

This does not mean that clopidogrel is “safe” in dengue. Rather, the rationale is that when platelet inhibition is still necessary, a less potent P2Y12 strategy may be preferable when clinically acceptable.

Ticagrelor and prasugrel provide more potent platelet inhibition than clopidogrel and have important bleeding considerations in cardiovascular populations. However, direct comparative trials of these agents in dengue are lacking.

Therefore, switching should not be automatic. The original indication, timing of PCI/ACS, platelet trajectory and thrombotic risk should all be considered.

A practical way to think about the patient

Instead of asking:

“Should I stop DAPT because the platelets are low?”

think through the following sequence:

1. Why is the patient receiving DAPT?

Recent PCI?
Recent ACS?
Long-term secondary prevention?

2. When was the PCI?

Very recent PCI and remote PCI after completion of the intended DAPT period are different clinical situations.

3. What are the platelets doing?

Not simply: “Platelets = 60,000.”

But: “Are they falling, stable or recovering?”

4. Is there active bleeding?

Look for:

• hematemesis

• melena

• gastrointestinal bleeding

• significant mucosal bleeding

• intracranial bleeding

• clinically significant hemorrhage

5. Is the patient entering the dengue critical phase?

Consider:

• plasma leakage

• rising hematocrit

• hemodynamic instability

• organ involvement

• rapidly falling platelet count

6. What is the thrombotic risk?

The consequences of interrupting DAPT are not the same in every patient.

7. Reassess repeatedly

A decision made on day 2 of dengue may not be appropriate on day 5.

Likewise, a temporary modification made during the platelet nadir may need to be reconsidered during recovery.

What about platelet transfusion?

Platelet transfusion should not automatically be given simply because a patient is receiving DAPT.

The 2026 Brazilian position statement discusses platelet transfusion in selected patients with very recent PCI and severe thrombocytopenia when it is being considered to support necessary antiplatelet therapy. Such decisions require specialist assessment rather than applying a universal transfusion threshold. (ABCCardiol)

A simple bedside checklist

When a patient with dengue is receiving DAPT, document:

DAPT indication
↓
Date and indication of PCI/ACS
↓
Current aspirin + P2Y12 agent
↓
Current platelet count AND trajectory
↓
Active bleeding?
↓
Plasma leakage/critical phase?
↓
Hematocrit and hemodynamic status
↓
Thrombotic risk
↓
Cardiology/interventional cardiology input when appropriate
↓
Reassess as dengue evolves

The clinical pharmacology perspective

DAPT is often treated as though it were a simple “continue versus stop” decision.

In dengue, it is better understood as a moving risk–benefit problem.

Platelet numbers can change substantially over hours to days. Platelet function may also be abnormal. Meanwhile, the pharmacodynamic effects of aspirin and P2Y12 inhibition do not disappear simply because the platelet count has fallen.

Therefore: The patient's antiplatelet decision may need to change as the dengue illness changes.

The relevant information during handover is not simply: “Patient is on DAPT.”

It is: Why is DAPT required? When did PCI/ACS occur? Which P2Y12 inhibitor is being used? What is the current platelet count and trajectory? Is there bleeding? Is there plasma leakage? What clinical change will trigger reassessment?

The bottom line

DAPT during dengue represents a collision between two clinically important risks:

Bleeding from dengue versus thrombosis from inadequate antiplatelet protection.

The platelet count is important, but it should not be the only variable driving the decision.

The patient's DAPT indication, time since PCI/ACS, platelet trajectory, active bleeding, dengue phase, plasma leakage and overall thrombotic risk should all be considered.

The 2023 Indian dengue guideline provides the India-specific framework for careful monitoring and identifies circumstances in which antiplatelet therapy may be discontinued. (NCVBDC)

The newer 2026 dengue position papers provide more detailed approaches, including platelet-count-based recommendations and a preference for clopidogrel in selected situations where P2Y12 inhibition remains necessary. However, these recommendations remain largely expert-consensus approaches rather than evidence from dengue-specific randomized trials. (Frontiers)

For clinicians, the safest conceptual approach is therefore:

Don't ask only “What is the platelet count?” Ask “Why does this patient need antiplatelet therapy, what is happening to the bleeding risk today, and how has the balance changed since yesterday?”

Key references

1. National Center for Vector Borne Diseases Control, Government of India. National Guidelines for Clinical Management of Dengue Fever. 2023. (NCVBDC)

2. Nilsen DWT, Leon De La Fuente R. Position paper on the management of antithrombotic therapy in patients with dengue. Front Trop Dis. 2026;7:1741612. (Frontiers)

3. Pitta FG, Ribeiro MOL, Pesaro AE, et al. Position Statement on the Management of Antithrombotic and Anticoagulant Therapy in Dengue – 2026. Arq Bras Cardiol. 2026;123(4):e20260216. (ABCCardiol)

4. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. J Am Coll Cardiol. 2023. (JACC)

5. Aditya W, Yap J, Chlebicki P, Chan WHW, Tan JWC. Management of anti-thrombotic therapy in patients with recent percutaneous coronary intervention and acute dengue infection: a case series. Singapore Med J. 2019.

Educational note: This is a clinician-oriented educational review, not a substitute for patient-specific cardiology/interventional cardiology and dengue management. The platelet thresholds from recent dengue position statements should not be interpreted as universally validated automatic stop/continue rules.